Generic selectors
Exact matches only
Search in title
Search in content
Post Type Selectors
Call Anytime 24/7 1-800-777-4141

Generic selectors
Exact matches only
Search in title
Search in content
Post Type Selectors
Free consultation

REPRESENTING THE PEOPLE AGAINST THE POWERFUL

OZEMPIC MAY CAUSE GASTROPARESIS AND VISION LOSS

IF YOU OR A LOVED ONE USED OZEMPIC AS A WEIGHT LOSS DRUG AND HAVE HAD INTESTINAL OR VISION PROBLEMS YOU MAY BE ENTITLED TO SUBSTANTIAL COMPENSATION.

ozempic lawsuit

Justice For Ozempic Users

If you or a loved one used Ozempic as a weight loss drug and have had Intestinal or vision problems you may be entitled to substantial compensation.  Talk to an AVA Legal Expert today to understand all your options.
FREE CASE EVALUATION

Ozempic in the news

ABout ozempic and what makes it dangerous?

Semaglutide is an anti-diabetic and weight loss medication developed in 2012 by Novo Nordisk, commonly sold by the brand names Ozempic and Wegovy. This drug increases insulin secretion and blood sugar disposal by imitating the action of peptides that improve glycemic control. This drug also changes the appetite of individuals who take this drug by slowing down the process of emptying the stomach. 
Since its FDA approval in 2017, Semaglutide has been prescribed for diabetes control and off-label weight loss purposes with once-weekly subcutaneous doses of Ozempic and Wegovy being used for weight management. Doctors generally only prescribe drugs for off-label use if all other drugs approved to treat a condition yield unsuccessful results. However, with the increased popularity of Semaglutide because of celebrity testimonials touting its success with cosmetic weight loss, Ozempic has become mainstream for doctors to prescribe it off-label for weight management.

SIDE EFFECTS OF OZEMPIC

With the continued use of this drug, recent studies have shown that diabetics taking Ozempic have reported serious complications of:
GASTROPARESIS
pancreatitis
acute kidney injuries
and intestinal blockages
Between 2018 and March 31st of 2023, more than 13,000 cases of adverse events related to the continued use of Ozempic have been reported to the FDA. Among those cases, 5,639 of them were reported to be serious, and 148 deaths have been attributed to the drug.

CONTACT OUR LEGAL TEAM FOR A FREE CASE EVALUATION

AVA LAW GROUP CAN HELP

CONNECT WITH OUR
LEGAL TEAM TODAY

If you or a loved one used Ozempic as a weight loss drug and have had Gastroparesis* or vision problems* you may be entitled to substantial compensation. Talk to an AVA Legal Expert today to understand all your options.

CONTACT US ANYTIME

1-800-800-1997

Hidden Danger: Ozempic and the Risk of Gastroparesis

Gastroparesis, sometimes referred to as stomach paralysis, is a condition where the stomach empties its contents slower than normal after eating. Despite its alarming name, gastroparesis does not cause true paralysis and is a reversible and expected effect of taking GLP-1 drugs like Ozempic. New research presented at Digestive Disease Week 2024 has highlighted a link between these medications and gastroparesis, showing that patients on GLP-1 drugs are more likely to develop this condition. However, experts emphasize that the overall risk remains low and the condition is reversible once the medication is stopped. Gastroparesis is part of how these drugs help control appetite and weight loss.

Ozempic and Vision Risks: What You Need to Know

The diabetes drug semaglutide, marketed as Ozempic, Wegovy, and Rybelsus, has proven effective in controlling blood sugar and aiding weight loss. However, recent studies have revealed alarming side effects on eye health, such as blurred vision and the worsening of diabetic retinopathy. Semaglutide can alter the shape of the eye's lens due to fluctuations in blood sugar levels, causing temporary vision changes. Additionally, there may be an increased risk of a severe eye condition called non-arteritic anterior ischemic optic neuropathy (NAION), though more research is needed to confirm this link. Patients should be aware of these potential risks and consult with their healthcare providers for informed decision-making.

LET’S LOOK AT THE LATEST STUDIES

In March of 2023, researchers released a study that found a significantly increased risk of intestinal obstruction with the continued use of Semaglutide, because the drug is known to reduce motility in the gut. The small intestine is primarily affected by these obstructions, becoming inelastic and fibrotic due to the change in gut motility which in turn causes obstructions. These obstructions are potentially fatal conditions that require surgery to prevent severe injury or death. In the study, type 2 diabetics were shown to be at a risk of 4.5 times higher than others who used other glucose control medications.
In addition to the potentially fatal risk of intestinal obstruction, Ozempic has been known in recent years to potentially cause fecal incontinence and/or constipation. Numerous individuals who have used the drug report said that they have passed stools in bed at night. Still, others have reported that they are uncomfortable with leaving their homes because they are afraid of experiencing an episode of fecal incontinence in public. In spite of these reports, Novo Nordisk has yet to place a warning or mention of this serious side effect that is linked to this drug.
We make walking through the legal process easy

Problem Solving is our promise

We provide a team of attorney, paralegals, and case managers to clients at no upfront cost.
AVA Law Group eliminates the confusion of filing a claim by working on your claim and, if necessary, connecting you with one our many partner firms that fits your needs and will get you the best results.
We’re available 24/7 to provide you with the information you need about case qualification.

Contact Us Today for your free, in-depth case evaluation

We're on Your Side
We're available 24/7
no fees unless you win

Free in-depth 
no obligation case evaluation

envelopeprinterusersphone-handsetmap-markercalendar-fullbubblecrossmenuchevron-downarrow-right
linkedin facebook pinterest youtube rss twitter instagram facebook-blank rss-blank linkedin-blank pinterest youtube twitter instagram